No information is available on the clinical use of idelalisib during breastfeeding. Because idelalisib is more than 84% bound to plasma proteins, the amount in milk is likely to be low. It is sometimes given in combination with rituximab, which may increase the risk to the infant. The manufacturer recommends that breastfeeding be discontinued during idelalisib therapy and for at least 1 month after the last dose.
关于idelalisib在母乳喂养期间的临床应用尚无可用信息。由于idelalisib与血浆蛋白的结合率超过84%，其在乳汁中的含量可能较低。它有时与利妥昔单抗联合使用，这可能会增加对婴儿的风险。制造商建议在idelalisib治疗期间及最后一剂后至少1个月内停止母乳喂养。
